β-NADP-sodium salt | CAS:1184-16-3

We serve β-NADP-sodium salt CAS:1184-16-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
β-NADP-sodium salt

Chemical Name:β-NADP-sodium salt
CAS.NO:1184-16-3
Synonyms:β-NADP-sodium salt
Triphosphopyridine nucleotide, sodium salt, hydrate
β-NADP-Na
NADP (sodium salt)
 
Physical and Chemical Properties:
Melting Point 175-178ºC
Molecular Formula C21H27N7NaO17P3
Molecular Weight 765.387
Exact Mass 765.057373
PSA 399.88000
Storage condition −20°C
 
Description:
Appearance:White solid
Assay:≥98%(HPLC) Powder: ≥75% aqueous solution
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Use:Biotransformation and biological reagents.



Contact us for information like 5,7-Dihydro-2-methylthieno[3,4-d]pyrimidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,NADP (sodium salt) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,β-NADP-Na Use and application,5,7-Dihydro-2-methylthieno[3,4-d]pyrimidine technical grade,usp/ep/jp grade.


Related News: The news, however, was greeted with skepticism online in China, with many — including numerous medical experts — questioning whether the findings were supported by clinical evidence from treating coronavirus patients.CIS-5,8,11,14,17-EICOSAPENTAENOIC ACID METHYL ESTER manufacturer Coupled with the poor global pesticide industry situation this year, the weakening of downstream customer demand has affected the sales of pesticide intermediates.N-(tert-Butoxycarbonyl)-4-piperidone supplier A 40-year-old Chinese woman also tested positive. She was already in quarantine as she is related to another patient who contracted the virus.3-chloropyridine-2-carboxylic acid vendor Professionally produce and submit DMF files, and supplement data at any time during the patent challenge of formulation companies.Many branded versions of drugs are currently more expensive in China than in other major markets. They could now be subjected to a centralized procurement program where manufacturers will have to go through a bidding process to get the right to supply drugs to public hospitals, the National Health Commission said in a document published on late Friday.